Status:
UNKNOWN
Use of Fc-MBL to Detect and Monitor the Presence of PAMPs During Septic Shock
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
Harvard Medical School (HMS and HSDM)
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Use Mannose Binding Lectin (MBL) as a biomarker to measure levels of Pathogen- Associated Molecular Patterns (PAMP) during septic shock. This will allow evaluating interest of this biomarker to monito...
Detailed Description
Septic shock still represent a major cause of admission in intensive care unit, incidence of severe sepsis is increasing, even in western countries, due to aging populations and comorbidities. Definit...
Eligibility Criteria
Inclusion
- Adult patients
- Hospitalized in Intensive Care Unit for sepsis of any etiology
- Patients with shock criteria: defined by a hypotension, hyperlactatemia, the use of vasopressive drugs.
- Patient affiliated to a social security scheme- Patient giving consent
Exclusion
- Minor patients
- Organ transplant
- Immunosuppressive drugs, other than corticosteroids
- Patients who decline participating to the assay
- Persons placed under legal protection, guardianship
- Pregnant woman
- Subject participating in another search including a exclusion period still in progress at pre-inclusion
Key Trial Info
Start Date :
October 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 18 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03457038
Start Date
October 18 2018
End Date
July 18 2019
Last Update
April 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Toulouse
Toulouse, France, 31059